- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04247750
Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP) (THALA-RAP)
Treatment of Beta-thalassemia Patients With Rapamycin (Sirolimus): From Pre-clinical Research to a Clinical Trial" - "Trattamento di Pazienti Con Beta-talassemia Con Rapamicina (Sirolimus): Dalla Ricerca Pre-clinica ad Uno Studio Clinico
Study Overview
Detailed Description
The general aim of this protocol is to demonstrate the applicability of a personalised and precision medicine approach in beta-thalassaemia; the clinical trial setting repurposes a drug, namely sirolimus. The presence of high Fetal Hemoglobin (HbF) levels is considered a condition predictive of a favourable outcome in thalassaemia. Its increase induced by pharmacological agents is considered a potential way to improve the clinical status of the patients. In terms of efficacy analysis, the investigators will focus their attention on HbF levels.
Primary objective:
• The suitability evaluation of sirolimus for the treatment of beta-thalassemia patients within the frame of a comprehensive project aimed at the reduction of their transfusions need, with consequent amelioration of their quality of life. The purpose can be achieved through increasing of HbF levels pharmacologically mediated, with verification of a prerequisite, namely the correlation between the induction of HbF in vitro and in vivo in single patients.
Secondary objectives:
- To assess the safety of sirolimus and correlation between administered dose and blood levels in beta-thalassemia patients
- To assess the influence of sirolimus on transfusion regimen
- To assess the effect of sirolimus on the hematopoietic and immune system of thalassemia patients.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Roberto Gambari, Ph.D.
- Phone Number: 00390532974443
- Email: roberto.gambari@unife.it
Study Contact Backup
- Name: Maria Rita Gamberini, MD
- Phone Number: 00390532239549
- Email: m.gamberini@ospfe.it
Study Locations
-
-
FE
-
Ferrara, FE, Italy, 44121
- Recruiting
- University of Ferrara Department of Life Sciences and Biotechnology
-
Contact:
- Roberto Gambari, PhD
- Phone Number: 00390532974443
- Email: roberto.gambari@unife.it
-
Ferrara, FE, Italy, 44124
- Recruiting
- Day Hospital Thalassaemia and Haemoglobinopathies (DHTE) - Azienda Ospedaliero-Universitaria S.Anna of Ferrara
-
Contact:
- Maria Rita Gamberini, Dr
- Phone Number: 00390532239549
- Email: m.gamberini@ospfe.it
-
Contact:
- Monica Fortini, BSc
- Phone Number: 00390532237349
- Email: frtmnc@unife.it
-
-
Fi
-
Firenze, Fi, Italy, 50139
- Recruiting
- Thalassemia and Hemoglobinopathies Center Azienda Ospedaliero Universitaria Meyer
-
Contact:
- Tommaso Casini, Dr
- Phone Number: 0039 055 5662580
- Email: tommaso.casini@meyer.it
-
-
Pi
-
Pisa, Pi, Italy, 56126
- Recruiting
- Pediatric oncohematology Azienda Ospedaliero Universitaria Pisana Ospedale Santa Chiara
-
Contact:
- Francesco Massei, Dr
- Phone Number: 0039 050 992842
- Email: f.massei@med.unipi.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients over 18 years of age;
- Patients able to understand the informed consent and to sign it before any study procedure;
- Patients with β0/β0 and β+/β0 thalassaemia genotype;
- Documented diagnosis of major or intermediate thalassemia transfusion-dependent (number of transfusions not less than 8 over the past 12 months before selection);
- On regular transfusion since at least 6 years;
- Splenectomy performed at least 60 days before selection or spleen largest dimensions < 20 cm as detected by abdominal echography;
- Female participants who are surgically sterilised/hysterectomised or post-menopausal for longer than 2 years or female participants of childbearing potential using and/or willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or using any other method considered sufficiently reliable by the investigator in individual cases. Patients must be counselled concerning measures to be used to prevent pregnancy and potential toxicities prior to the first dose of sirolimus;
- Patient willing to follow all the study requirements and perform all the study visits and to cooperate with the investigator;
- Patient followed by the same clinical site since at least 6 months.
Note that patients will be treated with oral sirolimus only in the case their Erythroid Precursor Cells (ErPCs) are responsive to the in vitro treatment with sirolimus according to laboratory-specific definition (≥ 20% increase of HbF in comparison with samples not treated with sirolimus);
Exclusion Criteria:
- Patient treated with hydroxyurea at selection visit or in the last 6 months;
- Ongoing treatment with drugs possibly affecting sirolimus actions;
- Documented aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3x Upper Limit of Normal (ULN) at selection;
- Documented Platelet count <150.000/microliter and >1.000.000/microliter at selection;
- Heart failure as classified by the New York Heart Association (NYHA) classification 3 or higher;
- Uncontrolled hypertension defined as systolic blood pressure (BP) ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg;
- Significant arrhythmia requiring treatment,
- Corrected QT interval> 450 msec on selection ECG;
- Ejection fraction <50% by echocardiogram, multiple gated acquisition scan or cardiac magnetic resonance;
- Myocardial infarction within 6 months prior to selection;
- Positivity for human immunodeficiency virus (HIV) antibody, active hepatitis B (HBV) or hepatitis C (HCV) as demonstrated by the presence of hepatitis B surface antigen (HBsAg) and a positive HCV-RNA test, HBcAb and HBV-DNA positivity
- White blood cell [WBC] count <3000 cells per μL and/or Granulocytes <1500/mm3;
- Total cholesterol > 240 mg/dl;
- Triglycerides > 200 mg/dl;
- Proteinuria with urinary protein >1g/24 hrs;
- Current participation in another trial with an investigational drug or experimental device, or inclusion in another trial with an investigational drug or experimental device within the preceding month;
- Major surgery (including splenectomy) within 60 days before selection (patients must have fully recovered from any previous surgery);
- Iron chelation therapy changed in the last 3 months prior to selection (note that Deferiprone is not accepted as a chelation therapy drug in this study while Desferrioxamine and Deferasirox are tolerated at stable dose);
- Current treatment with macrolide antibiotics (clarithromycin);
- Pregnant or lactating women;
- History of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the experimental drug;
- Treatment with live vaccines within 90 days preceding the selection;
- Subject with history or current malignancies (solid tumours and haematological malignancies) or presence of masses/tumour detected by ultrasound at selection;
- Subject with any significant medical condition and/or laboratory abnormality considered by the investigator as not adequately controlled at the time of selection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Open label trial
Sirolimus 0.5 mg tablets
|
Daily administration of 1 or more tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of fetal hemoglobin level
Time Frame: 360 days
|
Fetal hemoglobin level in peripheral blood at day 360 compared to day 0, assessed through high pressure liquid chromatography (HPLC)
|
360 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of fetal hemoglobin level
Time Frame: 90-180 days
|
Fetal hemoglobin level in peripheral blood at days 90 and 180 compared to day 0, assessed through HPLC
|
90-180 days
|
Change from baseline of γ-globin expression
Time Frame: 90-180-360 days
|
Level of induction of the γ-globin expression at day 90, 180 and 360 compared to day 0
|
90-180-360 days
|
Change from baseline of biomarkers for erythropoiesis
Time Frame: 180-360 days
|
- Evaluation of the Reticulocytes number at day 180 and 360 compared to baseline.
|
180-360 days
|
Change from baseline of biomarkers for erythropoiesis
Time Frame: 180-360 days
|
- Evaluation of the Nucleated red blood cells number at day 180 and 360 compared to baseline.
|
180-360 days
|
Change from baseline of biomarkers for erythropoiesis
Time Frame: 180-360 days
|
- Evaluation of the erythropoietin level at day 180 and 360 compared to baseline.
|
180-360 days
|
Change from baseline of biomarkers for erythropoiesis
Time Frame: 180-360 days
|
- Evaluation of the serum transferrin receptor level at day 180 and 360 compared to baseline.
|
180-360 days
|
Change from baseline of biomarkers for haemolysis
Time Frame: 180-360 days
|
- - Evaluation of the biomarkers for haemolysis level at day 180 and 360 compared to baseline.
Biomarkers will include: serum bilirubin level
|
180-360 days
|
Change from baseline of biomarkers for haemolysis
Time Frame: 180-360 days
|
- - Evaluation of the biomarkers for haemolysis level at day 180 and 360 compared to baseline.
Biomarkers will include: serum lactate dehydrogenase (LDH) level
|
180-360 days
|
Change from baseline of tranfusion needs
Time Frame: 360 days
|
Measurement of the total blood quantity (in mL) transfused (day -360 to -180, day -180 to 0, day 0 to 180, day 180 to 360)
|
360 days
|
Change from baseline of tranfusion needs
Time Frame: 360 days
|
Recording of the number of transfusions done in a semester (day -360 to -180, day -180 to 0, day 0 to 180, day 180 to 360)
|
360 days
|
Change from baseline of Iron status
Time Frame: 180-360 days
|
• Evaluation of the intake of iron chelators at days 180 and 360 compared to baseline
|
180-360 days
|
Change from baseline of Iron status
Time Frame: 90-180-360 days
|
• Evaluation of serum ferritin level at day 90, 180 and 360 in comparison with day 0
|
90-180-360 days
|
Change from baseline of Immune function
Time Frame: 90-360 days
|
• Peripheral blood immunophenotype-Lymphocyte subsets at day 90 and 360 compared to day 0
|
90-360 days
|
Change from baseline of Immune function
Time Frame: 90-360 days
|
• Quantitative analysis of ImmunoglobulinG/ImmunoglobulinA/ImunoglobulinM at day 90 and 360 compared to day 0
|
90-360 days
|
Change from baseline of Quality of Life
Time Frame: 360 days
|
Evaluation of the patient quality of life at 6 and 12 months compared to baseline through Transfusion-dependent Quality of Life questionnaire (TranQol), measuring specifically the quality of life in patients with thalassemia.
The TranQol is a disease-specific Quality of Life measure that has been shown to be valid and reliable (Klaassen et al, British Journal of Haematology, 2014, 164, 431-437).
On a total scale of 0-100, higher values always represent a better outcome.
The questions are grouped into four domains: physical health, emotional health, family functioning, and school and career functioning.
The adult self-report questionnaires include a fifth category on sexual activity which is only one item.
Subscales are summed
|
360 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Thalassemia
- beta-Thalassemia
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- 2018-001469-18 (EudraCT num)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Beta-Thalassemia
-
M.D. Anderson Cancer CenterWithdrawnSickle Cell Disease | Sickle Beta Thalassemia | Beta Thalassemia Major | Sickle Cell-SS Disease | Sickle Beta 0 Thalassemia | Sickle Beta Plus ThalassemiaUnited States
-
CelgeneTerminatedBeta Thalassemia Intermedia | Beta Thalassemia MajorFrance, United Kingdom, Italy, Greece
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Editas Medicine, Inc.RecruitingHemoglobinopathies | Thalassemia Major | Thalassemia Intermedia | Transfusion Dependent Beta ThalassemiaUnited States, Canada
-
Ionis Pharmaceuticals, Inc.TerminatedBeta Thalassemia IntermediaAustralia, Thailand, Greece, Lebanon, Turkey
-
Agios Pharmaceuticals, Inc.Active, not recruitingTransfusion-dependent Alpha-Thalassemia | Transfusion-dependent Beta-ThalassemiaSpain, Taiwan, Thailand, United States, France, Canada, Malaysia, Germany, Netherlands, Bulgaria, United Kingdom, Turkey, Italy, Greece, United Arab Emirates, Brazil, Denmark, Lebanon, Saudi Arabia
-
Agios Pharmaceuticals, Inc.Active, not recruitingNon-Transfusion-dependent Alpha-Thalassemia | Non-Transfusion-dependent Beta-ThalassemiaSpain, Taiwan, Thailand, United Kingdom, Malaysia, United States, Netherlands, Bulgaria, Turkey, Italy, Canada, Brazil, France, United Arab Emirates, Denmark, Greece, Lebanon, Saudi Arabia
-
Vifor (International) Inc.Labcorp Corporation of America Holdings, IncCompletedBeta-Thalassemia | Non-transfusion-dependent ThalassemiaGreece, Israel, Italy, Lebanon, Thailand
-
Children's Hospital of PhiladelphiaNot yet recruiting
-
CorrectSequence Therapeutics Co., LtdFirst Affiliated Hospital of Guangxi Medical UniversityNot yet recruiting
Clinical Trials on Sirolimus 0.5 mg
-
Andrew J. Armstrong, MDCompletedProstate CancerUnited States
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesChina
-
Atox Bio LtdTerminatedAcute Kidney Injury | Peritonitis | Necrotizing Soft Tissue InfectionUnited States, France
-
Hoffmann-La RocheCompletedFragile X SyndromeFrance, Spain, United States, Peru, Canada, United Kingdom, Chile, Argentina, Mexico, Sweden
-
Rare Partners srl Impresa SocialeUniversità degli Studi di FerraraCompletedBeta-ThalassemiaItaly
-
AsclepiX Therapeutics, Inc.TerminatedDiabetic Macular Edema (DME)United States
-
AsclepiX Therapeutics, Inc.TerminatedNeovascular Age-Related Macular Degeneration (nAMD)United States
-
Cara Therapeutics, Inc.CompletedPruritus | Atopic DermatitisUnited States, Canada
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Novo Nordisk A/SCompleted